Updates are available Correction dated 2025-07-23
Click to view Correction: https://doi.org/10.1038/s43018-025-01036-8
-
Authors
Petroni, Giulia https://orcid.org/0000-0002-0558-5322
Galassi, Claudia
Gouin, Kenneth H. III
Chen, Hsiang-Han https://orcid.org/0000-0003-1329-3298
Buqué, Aitziber https://orcid.org/0000-0002-7698-8778
Bloy, Norma
Yamazaki, Takahiro https://orcid.org/0000-0002-7420-4394
Sato, Ai https://orcid.org/0000-0002-5408-2596
Beltrán-Visiedo, Manuel https://orcid.org/0000-0002-7977-8020
Campia, Ginevra
Jiménez-Cortegana, Carlos
Shah, Aagam
Kirchmair, Alexander https://orcid.org/0000-0003-2284-7424
Massa, Chiara
Wickenhauser, Claudia
de Andrea, Carlos Eduardo
Navarro-Rubio, Belén
Serrano-Mendioroz, Irantzu
Navarro Manzano, Esther
Satty, Alexandra M.
Rippon, Brady
Finotello, Francesca https://orcid.org/0000-0003-0712-4658
Trajanoski, Zlatko https://orcid.org/0000-0002-0636-7351
Zhou, Xi Kathy https://orcid.org/0000-0002-8942-439X
Scandura, Joseph M. https://orcid.org/0000-0002-9525-143X
García-Martínez, Elena
Ayala de la Peña, Francisco https://orcid.org/0000-0001-6311-920X
Rodríguez-Ruiz, María Esperanza
Seliger, Barbara
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
Basho, Reva K.
Shiao, Stephen L.
McArthur, Heather L.
Formenti, Silvia C.
Knott, Simon R. V. https://orcid.org/0000-0002-4018-7653
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (#BC210945, #BC210945)
EIF | Stand Up To Cancer (#ZP-6177, #ZP-6177)
- License Information
-
More Information
Article History
Received: 1 December 2023
Accepted: 23 May 2025
First Online: 7 July 2025
Change Date: 23 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-025-01036-8
Competing interests
: F.F. has been holding research contracts with iOnctura. M.E.R.-R. reports receiving research funding from Roche and Bioncotech. She also has received speaker’s bureau honoraria from Bristol Myers Squibb (BMS) and Roche. H.L.M. is/has been holding research contracts with BMS, MedImmune, LLC/AstraZeneca, BTG and Merck and has received consulting/advisory honoraria from Amgen, BMS, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi-Sankyo, Seattle Genetics, AstraZeneca, Gilead, Crown Bioscience and TapImmune. S.C.F. is/has been holding research contracts with Merck, Varian, BMS, Celldex, Regeneron, Eisai and Eli Lilly and has received consulting/advisory honoraria from Bayer, BMS, Varian, Elekta, Regeneron, Eisai, AstraZeneca, MedImmune, Merck US, EMD Serono, Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, View Ray and Nanobiotix. S.R.V.K. is a founder and consultant at Transomic Technologies and Faeth Therapeutics. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom and the Luke Heller TECPR2 Foundation and holds Promontory stock options. All other authors have no conflicts to declare.
